{
    "FileId": "34438_4",
    "Title": "<em>Glycemic</em> Control",
    "PremiumContentType": "off-label",
    "Headings": [
        {
            "HeadingId": 1,
            "Heading": "<h2>Summary</h2>",
            "Content": [
                "<ul>\n        \n\t\t\t\t<li>Saxenda<sup>&#xAE;</sup> is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of &#x2265;30 kg/m<sup>2</sup> (obese) or BMI &#x2265;27 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).<sup>1</sup></li>\n        \n\t\t\t\t<ul> \n\t\t\t\t\t<li>Because Saxenda<sup>&#xAE;</sup> is a GLP1-receptor agonist, it can lower blood glucose. Monitor blood glucose parameters prior to starting Saxenda<sup>&#xAE; </sup>and during Saxenda<sup>&#xAE;</sup> treatment in patients with type 2 diabetes. If needed, adjust co-administered anti-diabetic drugs based on glucose monitoring results and risk of hypoglycemia.<sup>1</sup></li>\n        \n\t\t\t\t</ul>\n      \n\t\t\t\t<li>Change from baseline in various <em>glycemic</em> control parameters was a secondary endpoint in the Novo Nordisk Phase 3 SCALE&#x2122; (<b>S</b>atiety and <b>C</b>linical <b>A</b>diposity &#x2013; <b>L</b>iraglutide <b>E</b>vidence in Non-diabetic and Diabetic people) program for Saxenda<sup>&#xAE;</sup>.<sup> </sup><em>Glycemic</em> status at baseline can be seen in <a class=\"tabletarget\" data-table=\"table1\"><b> Table 1</b></a>.</li>\n  \n\t\t\t\t<li>In a study of patients without diabetes, Saxenda<sup>&#xAE; </sup>was associated with improvements in fasting and postprandial glycemia, as well as overall <em>glycemic</em> control compared to placebo across the SCALE&#x2122; trials (<a class=\"tabletarget\" data-table=\"table2\"><b>Table 2</b></a>).<sup>2-6</sup></li>\n  \n\t\t\t\t<li>Patients with prediabetes were enrolled in SCALE&#x2122; Obesity and Prediabetes 3-year study (<a class=\"tabletarget\" data-table=\"table3\"><b>Table 3</b></a>).<sup>6</sup> Nine hundred and seventy (66%) of 1472 Saxenda<sup>&#xAE;</sup>-treated patients and 268 (36%) out of 738 of placebo-treated patients had reverted from prediabetes to having normal <em>glycemic</em> parameters (<i>P</i>&lt;.0001).</li>\n  \n\t\t\t\t<ul>\n    \n\t\t\t\t\t<li>Twenty-six (2%) of the 1472 Saxenda<sup>&#xAE;</sup>- treated patients and 46 patients (6%) on placebo developed type 2 diabetes over the 3-year study period.</li>\n  \n\t\t\t\t</ul>\n  \n\t\t\t\t<li>SCALE&#x2122; Diabetes enrolled patients who were overweight or obese with type 2 diabetes. More Saxenda<sup>&#xAE;</sup>-treated patients achieved A1C of &lt;7% and &lt;6.5% than those treated with liraglutide 1.8 mg or placebo (<a class=\"tabletarget\" data-table=\"table3\"><b>Table 3</b></a>).<sup>4</sup></li>\n  \n\t\t\t\t<li>The risk of hypoglycemia in patients receiving Saxenda<sup>&#xAE;</sup> treatment is:</li>\n  \n\t\t\t\t<ul>\n    \n\t\t\t\t\t<li>Low in patients without type 2 diabetes and prediabetes.<sup>2,3,6,7</sup> Most events were recorded at oral glucose tolerance test (OGTT) visits, and were not accompanied by symptoms.<sup>8</sup> None required third-party assistance (<a class=\"tabletarget\" data-table=\"table4\"><b>Table 4</b></a> and <a class=\"tabletarget\" data-table=\"table5\"><b>Table 5</b></a>).</li>\n    \n\t\t\t\t\t<ul>\n      \n\t\t\t\t\t\t<li>Spontaneously reported symptomatic episodes of unconfirmed hypoglycemia were reported by 46 (1.6%) of 2962 Saxenda<sup>&#xAE;</sup>-treated patients and 19 (1.1%) of 1729 placebo-treated patients.</li>\n    \n\t\t\t\t\t</ul>\n    \n\t\t\t\t\t<li>Comparable to liraglutide 1.8 mg but higher than placebo in patients with type 2 diabetes.</li>\n    \n\t\t\t\t\t<ul>\n      \n\t\t\t\t\t\t<li>The risk of hypoglycemia was higher in those patients taking a sulfonlyurea (SU) as background anti-diabetic medication, as compared to those who were not on SU therapy (<b>Table 6</b>).<sup>4</sup></li>\n      \n\t\t\t\t\t\t<li>Of subjects treated concomitantly with sulfonlyulreas, 3 out of 110 patients on Saxenda<sup>&#xAE; </sup>(2.7%), 2 out of 52 patients on liraglutide 1.8 mg (3.8%), and no patients on placebo experienced severe hypoglycemia.</li>\n    \n\t\t\t\t\t</ul>\n  \n\t\t\t\t</ul>\n\n\t\t\t</ul>"
            ]
        },
        {
            "HeadingId": 2,
            "Heading": "<h2>Prescribing Information</h2>",
            "Content": [
                "<p>The risk for serious hypoglycemia is increased when Saxenda<sup>&#xAE;</sup> is used in combination with insulin secretagogues (e.g., SUs). Therefore, patients may require a lower dose of SU (or other concomitantly administered insulin secretagogues in this setting. When initiating Saxenda<sup>&#xAE;</sup> in patients taking insulin secretagogues, consider reducing the dose of the insulin secretagogue (e.g., by one-half) to reduce the risk for hypoglycemia, and monitor blood glucose. Conversely, if discontinuing Saxenda<sup>&#xAE;</sup> in patients with type 2 diabetes, monitor for an increase in blood glucose.<sup>1</sup></p>"
            ]
        },
        {
            "HeadingId": 3,
            "Heading": "<h2>Overview of the Phase 3 Clinical Development Program</h2>",
            "Content": [
                "<p>Novo Nordisk has completed the Phase 3a SCALE&#x2122; (<b>S</b>atiety and <b>C</b>linical <b>A</b>diposity &#x2013; <b>L</b>iraglutide <b>E</b>vidence in Non-diabetic and Diabetic people) program for Saxenda<sup>&#xAE;</sup>, which included the randomized, double-blind placebo-controlled studies described in <a class=\"tabletarget\" data-table=\"table1\"><b>Table 1</b></a>.&#xA0; Across all studies, patients were randomized to Saxenda<sup>&#xAE;</sup> or placebo in combination with a 500 kcal/day deficit diet and increased physical activity.</p>\n\n\t\t\t<div class=\"table\" id=\"table1\">\n\t\t\t\t<p><b>Table 1. Overview of SCALE&#x2122; Studies</b></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122; Maintenance<sup>2,9</sup></b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122; Obesity and Prediabetes<sup>3,6</sup></b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122; Diabetes<sup>4</sup></b><sup>c</sup></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Sleep Apnea<sup>5</sup></b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Duration (weeks)</b></p></td>\n      <td valign=\"middle\"><p>56</p></td>\n      <td valign=\"middle\"><p>56</p></td>\n      <td valign=\"middle\"><p>160<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>56</p></td>\n      <td valign=\"middle\"><p>32</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Randomized Patients (N)</b></p></td>\n      <td valign=\"middle\"><p>422</p></td>\n      <td valign=\"middle\"><p>3731</p></td>\n      <td valign=\"middle\"><p>2285<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>846</p></td>\n      <td valign=\"middle\"><p>359</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>BMI Inclusion Criteria (kg/m<sup>2</sup>)</b></p></td>\n      <td valign=\"middle\"><p>&#x2265;27 with comorbidities or &#x2265;30</p></td>\n      <td valign=\"middle\"><p>&#x2265;27 with comorbidities or &#x2265;30</p></td>\n      <td valign=\"middle\"><p>&#x2265;27 with comorbidities or &#x2265;30</p></td>\n      <td valign=\"middle\"><p>&#x2265;27</p></td>\n      <td valign=\"middle\"><p>&#x2265; 30</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b><em>Glycemic</em> Status at Baseline (N (%))</b><sup>d,e</sup></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Normoglycemia</i></p></td>\n      <td valign=\"middle\"><p>171 (40.5)</p></td>\n      <td valign=\"middle\"><p>1446 (38.8)</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>132 (36.8)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Prediabetes</i></p></td>\n      <td valign=\"middle\"><p>251 (59.5)</p></td>\n      <td valign=\"middle\"><p>2285 (61.2) for 56 weeks</p>\n        <p>2285 (100) for 160 weeks</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>227 (63.2)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Type 2 Diabetes</i></p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>844 (100)</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n    </tr>\n  </tbody>\n</table>\n\n\t\t\t\t<ul>\n  \n\t\t\t\t\t<li>All patients receiving at least one dose of trial product</li>\n  \n\t\t\t\t\t<li>Patients with signs of prediabetes at screening were randomized to Saxenda<sup>&#xAE;</sup> (n=1505) or placebo (n=749) for an additional 104 weeks</li>\n  \n\t\t\t\t\t<li>Included a&#xA0; liraglutide 1.8 mg treatment arm</li>\n  \n\t\t\t\t\t<li>Defined according to American Diabetes Association 2010 criteria</li>\n  \n\t\t\t\t\t<li>Percentage is based on safety analysis set</li>\n\n\t\t\t\t</ul>\n\n\t\t\t\t<p><b>Abbreviation</b>: BMI: body mass index; kg: kilograms; m: meters; N: number of patients</p>\n\n\t\t\t</div>"
            ]
        },
        {
            "HeadingId": 4,
            "Heading": "<h2><em>Glycemic</em> Control in Phase 3 Trials</h2>",
            "Content": [
                "<p>Change from baseline in various <em>glycemic</em> control parameters was a secondary endpoint in all of the SCALE&#x2122; trials with Saxenda<sup>&#xAE;</sup>. Available results of these secondary endpoints are summarized in <a class=\"tabletarget\" data-table=\"table2\"><b>Table 2</b></a> in patients without diabetes, and in <a class=\"tabletarget\" data-table=\"table3\"><b>Table 3</b></a> for patients with prediabetes or with type 2 diabetes.<sup>2-6</sup> Effects of liraglutide, particularly at the higher dose (3 mg), are likely to be mediated by both direct weight-loss independent and weight-loss dependent mechanisms. The glucose lowering effects were most pronounced in patients with hyperglycemia.</p>\n\n\t\t\t<div class=\"table\" id=\"table2\">\n\t\t\t\t<p><b>Table 2. <em>Glycemic</em> Control in Phase 3 Trials of Saxenda<sup>&#xAE;</sup> in patients </b><b><i>WITHOUT </i>type 2 diabetes</b><b>.</b></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Maintenance<sup>2</sup></b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Obesity and Prediabetes<sup>3b</sup></b></p>\n        <p><b>(<i>56 weeks</i>)</b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Sleep Apnea<sup>5</sup> </b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=207)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo (N=206)</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=2437)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo (N=1225)</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=180)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo (N=179)</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Baseline A1C (%)</b></p></td>\n      <td valign=\"middle\"><p>5.6</p></td>\n      <td valign=\"middle\"><p>5.5</p></td>\n      <td valign=\"middle\"><p>5.6</p></td>\n      <td valign=\"middle\"><p>5.6</p></td>\n      <td valign=\"middle\"><p>5.7</p></td>\n      <td valign=\"middle\"><p>5.6</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>&#x394; A1C</i></p></td>\n      <td valign=\"middle\"><p>-0.1<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>+0.1</p></td>\n      <td valign=\"middle\"><p>-0.3<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>-0.06</p></td>\n      <td valign=\"middle\"><p>-0.4<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>-0.2</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Baseline FPG (mg/dL)</b></p></td>\n      <td valign=\"middle\"><p>102.6</p></td>\n      <td valign=\"middle\"><p>102.6</p></td>\n      <td valign=\"middle\"><p>95.9</p></td>\n      <td valign=\"middle\"><p>95.5</p></td>\n      <td valign=\"middle\"><p>97.2</p></td>\n      <td valign=\"middle\"><p>97.2</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>&#x394; FPG</i></p></td>\n      <td valign=\"middle\"><p>-9<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>-3.6</p></td>\n      <td valign=\"middle\"><p>-7.1<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>+0.1</p></td>\n      <td valign=\"middle\"><p>-3.6<sup>a</sup></p></td>\n      <td valign=\"middle\"><p>+3.6</p></td>\n    </tr>\n  </tbody>\n</table>\n\n\t\t\t\t<p>Baseline values are observed means; All data are for full analysis set (defined as all randomized patients who were exposed to at least one dose of trial product and had at least one post-baseline assessment of any endpoint) with last observation carried forward; missing values in grey shaded boxes indicate that endpoints were not assessed</p>\n<p><i><sup>a </sup>P</i>&lt;.0001 vs placebo</p>\n<p><sup>b</sup> Patients in the 56 weeks portion of the study included patients with BMI &#x2265; 27 kg/m<sup>2</sup> with one weight-related comorbidity or BMI &#x2265; 30 kg/m<sup>2</sup> AND prediabetes. </p>\n\n\t\t\t\t<p><b>Abbreviations</b>: A1C: glycosylated hemoglobin; FPG: fasting plasma glucose; N: Number of patients; PPG: post-prandial glucose</p>\n\n\t\t\t</div>\n\t\t\t<div class=\"table\" id=\"table3\">\n\t\t\t\t<p><b>Table 3. <em>Glycemic</em> parameters in Phase 3 Trials of Saxenda<sup>&#xAE;</sup> in patients </b><b><i>WITH</i></b><b> </b><b>prediabetes or type 2 diabetes</b><b>.</b></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Obesity and Prediabetes</b><sup>e</sup></p>\n        <p><b><i>(160 weeks)</i></b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Diabetes<sup>4</sup></b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=1505)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo (N=749)</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=412)</b></p></td>\n      <td valign=\"middle\"><p><b>Liraglutide 1.8 mg</b></p>\n        <p><b>(N=204)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo (N=211)</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Baseline A1C (%)</b></p></td>\n      <td valign=\"middle\"><p>5.8</p></td>\n      <td valign=\"middle\"><p>5.8</p></td>\n      <td valign=\"middle\"><p>7.9</p></td>\n      <td valign=\"middle\"><p>8</p></td>\n      <td valign=\"middle\"><p>7.9</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>&#x394; A1C</i></p></td>\n      <td valign=\"middle\"><p>-0.35<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>-0.14</p></td>\n      <td valign=\"middle\"><p>-1.3<sup>b,d</sup></p></td>\n      <td valign=\"middle\"><p>-1.1<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>-0.3</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>A1C &lt;7%</i></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>69.2<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>66.7<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>27.2</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>A1C &#x2264;6.5%</i></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>56.5<sup>b,d</sup></p></td>\n      <td valign=\"middle\"><p>45.6<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>15</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Baseline FPG (mg/dL)</b></p></td>\n      <td valign=\"middle\"><p>99</p></td>\n      <td valign=\"middle\"><p>99</p></td>\n      <td valign=\"middle\"><p>158.4</p></td>\n      <td valign=\"middle\"><p>160.4</p></td>\n      <td valign=\"middle\"><p>155.5</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>&#x394; FPG</i></p></td>\n      <td valign=\"middle\"><p>-6.7<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>+0.9</p></td>\n      <td valign=\"middle\"><p>-34.3<sup>b</sup></p></td>\n      <td valign=\"middle\"><p>-26.8</p></td>\n      <td valign=\"middle\"><p>-0.2</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Baseline PPG (mg/dL)</b></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>41.4</p></td>\n      <td valign=\"middle\"><p>43.2</p></td>\n      <td valign=\"middle\"><p>43.2</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>&#x394; Prandial glucose increment (mg/dL)</i><sup>a</sup></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>-16.2<sup>c</sup></p></td>\n      <td valign=\"middle\"><p>-12.6<sup>c</sup></p></td>\n      <td valign=\"middle\"><p>-5.4</p></td>\n    </tr>\n  </tbody>\n</table>\n\n\t\t\t\t<p>Baseline values are observed means; All data are for full analysis set (defined as all randomized patients who were exposed to at least one dose of trial product and had at least one post-baseline assessment of any endpoint) with last observation carried forward; missing values in grey shaded boxes indicate that endpoints were not assessed</p>\n\n\t\t\t\t<p><sup>a </sup>Based on 7-point self-measured plasma glucose profile, 90 minutes after meal initiation</p>\n<p><i><sup>b </sup>P</i>&lt;.0001 vs placebo</p>\n<p><i><sup>c </sup>P</i>&lt;.01 vs placebo</p>\n<p><i><sup>d </sup>P</i>=.01 vs liraglutide 1.8 mg</p>\n<p><sup>e </sup>Patients with prediabetes at screening continued on to an additional 104 weeks, for a total of 160 weeks of treatment.</p>\n\n\t\t\t\t<p><b>Abbreviations</b>: A1C: glycosylated hemoglobin; FPG: fasting plasma glucose; N: Number of patients; PPG: post-prandial glucose</p>\n\n\t\t\t</div>"
            ]
        },
        {
            "HeadingId": 5,
            "Heading": "<h2>Hypoglycemia with Saxenda<sup>&#xAE;</sup></h2>",
            "Content": [
                "<p><b><i>Prescribing Information - Section 6.1: Adverse Reactions, Clinical Trials Experience, Hypoglycemia</i></b></p>\n\t\t\t\n<p>During the clinical development of Saxenda<sup>&#xAE;</sup>, hypoglycemia in type 2 diabetes was a commonly reported adverse event (23% vs 12.7% with Saxenda<sup>&#xAE;</sup> and placebo, respectively), and therefore, is listed as&#xA0;a potential side effect of Saxenda<sup>&#xAE;</sup> in the Prescribing Information.<sup>1</sup> </p>\n<p>Saxenda<sup>&#xAE; </sup>can lower blood glucose. In a clinical trial involving patients with type 2 diabetes mellitus and overweight or obesity, severe hypoglycemia (defined as requiring the assistance of another person) occurred in 3 (0.7%) of 422 Saxenda<sup>&#xAE;</sup>-treated patients and in none of the 212 placebo-treated patients. Each of these 3 Saxenda<sup>&#xAE;</sup>-treated patients was also taking a sulfonylurea. In the same trial, among patients taking a sulfonylurea, documented symptomatic hypoglycemia (defined as documented symptoms of hypoglycemia in combination with a plasma glucose less than or equal to 70 mg/dL) occurred in 48 (43.6%) of 110 Saxenda<sup>&#xAE;</sup>-treated patients and 15 (27.3%) of 55 placebo-treated patients. The doses of sulfonylureas were reduced by 50% at the beginning of the trial per protocol. The frequency of hypoglycemia may be higher if the dose of sulfonylurea is not reduced. Among patients not taking a sulfonylurea, documented symptomatic hypoglycemia occurred in 49 (15.7%) of 312 Saxenda<sup>&#xAE;</sup>-treated patients and 12 (7.6%) of 157 placebo-treated patients.</p>\n<p>In Saxenda<sup>&#xAE; </sup>clinical trials involving patients without type 2 diabetes mellitus, there was no systematic capturing or reporting of hypoglycemia, as patients were not provided with blood glucose meters or hypoglycemia diaries. Spontaneously reported symptomatic episodes of unconfirmed hypoglycemia were reported by 46 (1.6%) of 2962 Saxenda<sup>&#xAE;</sup>-treated patients and 19 (1.1%) of 1729 placebo-treated patients. Fasting plasma glucose values obtained at routine clinic visits less than or equal to 70 mg/dL, irrespective of hypoglycemic symptoms, were reported as &#x201C;hypoglycemia&#x201D; in 92 (3.1%) Saxenda<sup>&#xAE;</sup>-treated patients and 13 (0.8%) placebo-treated patients.</p>\n\t\t\t\n<p><b><i>Clinical Trial Analysis</i></b></p>\n\n\t\t\t<p>Hypoglycemia events in patients without type 2 diabetes and with prediabetes are summarized in <a class=\"tabletarget\" data-table=\"table2\"><b>Table 4</b></a>.<sup>2,3,7</sup> Most events were recorded at OGTT visits, where no specific guidance was provided on when to report a low glucose value as a hypoglycemia adverse event, and were not accompanied by symptoms. None required third party assistance.</p>\n\t\t\t<div class=\"table\" id=\"table4\">\n\t\t\t\t\n<p><b>Table 4. Hypoglycemic Events in patients </b><b><i>WITHOUT </i>type 2 diabetes.</b><sup>2,3,7</sup></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Maintenance</b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;Obesity and Prediabetes<sup>a</sup></b></p>\n        <p><b><i>(56 weeks)</i></b></p></td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Sleep Apnea</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>N=212</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo N=210</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>N=2481</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo N=1242</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>N=180</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo N=179</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Hypoglycemia</b></p>\n        <p><b>( N, %)</b></p></td>\n      <td valign=\"middle\"><p>11</p>\n        <p>(5.2)</p></td>\n      <td valign=\"middle\"><p>5</p>\n        <p>(2.4)</p></td>\n      <td valign=\"middle\"><p>296 (11.9)</p></td>\n      <td valign=\"middle\"><p>41</p>\n        <p>(3.3)</p></td>\n      <td valign=\"middle\"><p>6</p>\n        <p>(3.4)</p></td>\n      <td valign=\"middle\"><p>3</p>\n        <p>(1.7)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Spontaneously Reported</i></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>32</p></td>\n      <td valign=\"middle\"><p>13</p></td>\n      <td valign=\"middle\"><p>2</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Reported at FPG visit</i></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>90</p></td>\n      <td valign=\"middle\"><p>10</p></td>\n      <td valign=\"middle\"><p>4</p></td>\n      <td valign=\"middle\"><p>4</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Reported at OGTT visit</i></p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>205</p></td>\n      <td valign=\"middle\"><p>18</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b># of hypo events</b></p></td>\n      <td valign=\"middle\"><p>18</p></td>\n      <td valign=\"middle\"><p>7</p></td>\n      <td valign=\"middle\"><p>431</p></td>\n      <td valign=\"middle\"><p>46</p></td>\n      <td valign=\"middle\"><p>6</p></td>\n      <td valign=\"middle\"><p>4</p></td>\n    </tr>\n  </tbody>\n</table>\n<p><sup>a</sup><sup> </sup>Patients in the 56 weeks portion of the study included patients with BMI &#x2265; 27 kg/m<sup>2</sup> with one weight-related comorbidity or BMI &#x2265; 30 kg/m<sup>2</sup> AND prediabetes.</p>\n\n\t\t\t\t<p><b>Abbreviations:</b> FPG: fasting plasma glucose; hypo: hypoglycemic; N: Number of patients; OGTT: oral glucose tolerance test</p>\n\n\t\t\t</div>\n\t\t\t<div class=\"table\" id=\"table5\">\n\t\t\t\t<p><b>Table 5. Hypoglycemic Events in patients </b><b><i>WITH </i>prediabetes<i><sup>6</sup></i></b></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>SCALE&#x2122;</b></p>\n        <p><b>Obesity and Prediabetes<sup>a</sup></b></p>\n        <p><b><i>(160 weeks)</i></b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p>\n        <p><b>(N=1470)</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo</b></p>\n        <p><b>(N=700)</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Hypoglycemia (N, %)</b></p></td>\n      <td valign=\"middle\"><p>293 (19.9)</p></td>\n      <td valign=\"middle\"><p>33 (4.7)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Spontaneously Reported</i></p></td>\n      <td valign=\"middle\"><p>50 (3.4)</p></td>\n      <td valign=\"middle\"><p>12 (1.7)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Reported at FPG visit</i></p></td>\n      <td valign=\"middle\"><p>62 (4.2)</p></td>\n      <td valign=\"middle\"><p>6 (0.9)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><i>Reported at OGTT visit</i></p></td>\n      <td valign=\"middle\"><p>235 (16)</p></td>\n      <td valign=\"middle\"><p>18 (2.6)</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Number of Hypoglycemic Events</b></p></td>\n      <td valign=\"middle\"><p>634</p></td>\n      <td valign=\"middle\"><p>49</p></td>\n    </tr>\n  </tbody>\n</table>\n\n\t\t\t\t<p><sup>a</sup> Patients&#xA0; with BMI &#x2265; 27 kg/m<sup>2</sup> with one weight-related comorbidity or BMI &#x2265; 30 kg/m<sup>2</sup></p>\n<p>AND prediabetes continued on to an additional 104 weeks, for a total of 160 weeks of treatment.</p>\n<p><b>Abbreviations:</b> FPG: fasting plasma glucose; N: Number of patients; OGTT: oral glucose tolerance test</p>\n\n\t\t\t</div>\n\t\t\t<p>In patients with type 2 diabetes, the risk of hypoglycemia with Saxenda<sup>&#xAE;</sup> was similar to liraglutide 1.8 mg but higher than placebo, indicating no increased risk associated with a higher liraglutide dose and greater weight loss.<sup>4</sup></p>\n\n\t\t\t<p>In the SCALE&#x2122; Diabetes trial, patients with type 2 diabetes were allowed to be on background treatment with 1-3 oral antidiabetic drugs (OADs), specifically metformin, SU, and thiazolidinedione; however, to reduce the risk of hypoglycemia, patients treated with a SU were required to reduce their dose by 50% or as close to 50% as possible based on dose options locally available. More patients on Saxenda<sup>&#xAE;</sup> (13.1%) were able to reduce their use of OADs after 56 weeks compared to liraglutide 1.8 mg (8.3%) and placebo (5.7%). In contrast, more patients in the placebo group (27%) and liraglutide 1.8 mg group (9.3%) increased use of OADs compared to Saxenda<sup>&#xAE;</sup> (5.1%).</p>\n<p>Patients taking SUs were 3-4 times more likely to experience a hypoglycemic episode compared with patients not taking SUs (<a class=\"tabletarget\" data-table=\"table6\"><b>Table 6</b></a>).<sup>8</sup></p>\n\n\t\t\t<div class=\"table\" id=\"table6\">\n\t\t\t\t<p><b>Table 6. Hypoglycemic Events in </b><b><i>WITH </i>type 2 diabetes</b><sup>4</sup></p>\n\n\t\t\t\t<table cellspacing=\"0\" cellpadding=\"0\">\n  <tbody>\n    <tr>\n      <td valign=\"middle\"><p><b>Hypoglycemia</b></p></td>\n      <td valign=\"middle\"><p><b>Saxenda<sup>&#xAE;</sup></b></p></td>\n      <td valign=\"middle\"><p><b>Liraglutide 1.8 mg</b></p></td>\n      <td valign=\"middle\"><p><b>Placebo</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p><b>N</b></p></td>\n      <td valign=\"middle\"><p><b>%</b></p></td>\n      <td valign=\"middle\"><p><b>E</b></p></td>\n      <td valign=\"middle\"><p><b>N</b></p></td>\n      <td valign=\"middle\"><p><b>%</b></p></td>\n      <td valign=\"middle\"><p><b>E</b></p></td>\n      <td valign=\"middle\"><p><b>N</b></p></td>\n      <td valign=\"middle\"><p><b>%</b></p></td>\n      <td valign=\"middle\"><p><b>E</b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b><i>Patients taking SUs as background OADs</i></b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>N</b></p></td>\n      <td valign=\"middle\"><p>110</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>52</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>55</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Severe</b></p></td>\n      <td valign=\"middle\"><p>3</p></td>\n      <td valign=\"middle\"><p>2.7</p></td>\n      <td valign=\"middle\"><p>5</p></td>\n      <td valign=\"middle\"><p>2</p></td>\n      <td valign=\"middle\"><p>3.8</p></td>\n      <td valign=\"middle\"><p>3</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Documented Symptomatic</b></p></td>\n      <td valign=\"middle\"><p>48</p></td>\n      <td valign=\"middle\"><p>43.6</p></td>\n      <td valign=\"middle\"><p>214</p></td>\n      <td valign=\"middle\"><p>23</p></td>\n      <td valign=\"middle\"><p>44.2</p></td>\n      <td valign=\"middle\"><p>109</p></td>\n      <td valign=\"middle\"><p>15</p></td>\n      <td valign=\"middle\"><p>27.3</p></td>\n      <td valign=\"middle\"><p>41</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b><i>Patients not taking SUs as background OADs</i></b></p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>N</b></p></td>\n      <td valign=\"middle\"><p>312</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>158</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\"><p>157</p></td>\n      <td valign=\"middle\">&#xA0;</td>\n      <td valign=\"middle\">&#xA0;</td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Severe</b></p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n      <td valign=\"middle\"><p>0</p></td>\n    </tr>\n    <tr>\n      <td valign=\"middle\"><p><b>Documented Symptomatic</b></p></td>\n      <td valign=\"middle\"><p>49</p></td>\n      <td valign=\"middle\"><p>15.7</p></td>\n      <td valign=\"middle\"><p>115</p></td>\n      <td valign=\"middle\"><p>24</p></td>\n      <td valign=\"middle\"><p>15.2</p></td>\n      <td valign=\"middle\"><p>71</p></td>\n      <td valign=\"middle\"><p>12</p></td>\n      <td valign=\"middle\"><p>7.6</p></td>\n      <td valign=\"middle\"><p>15</p></td>\n    </tr>\n  </tbody>\n</table>\n\n\t\t\t\t<p><b>Abbreviations</b>: E: number of hypoglycemic events; N: number of patients; OADs: oral anti-diabetics; SU: sulfonylurea</p>\n\n\t\t\t</div>\n\t\t\t<p>All severe episodes occurred in patients concomitantly treated with SUs, which are known to increase the risk of hypoglycemia in patients co-treated with a glucagon-like peptide-1 (GLP-1) receptor agonist.</p>"
            ]
        },
        {
            "HeadingId": 6,
            "Heading": "<p>References</p>",
            "Content": [
                "<p>1. Saxenda&#xAE; Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.</p>\n<p>2. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study<i>.</i> <i>International Journal of Obesity.</i> 2013;37(11):1443-1451.</p>\n<p>3. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management<i>.</i> <i>New England Journal of Medicine.</i> 2015;373(1):11-22.</p>\n<p>4. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial<i>.</i> <i>Jama-Journal of the American Medical Association.</i> 2015;314(7):687-699.</p>\n<p>5. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial<i>.</i> <i>Int J Obes (Lond).</i> 2016;40:1310-1319.</p>\n<p>6. le Roux C, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial<i>.</i> <i>Lancet.</i> 2017</p>\n<p>7. Data on File at Novo Nordisk Inc. Plainsboro, NJ. NN8022-3970 (SCALE Sleep Apnea), Oct 2013.</p>\n<p>8. Data on File at Novo Nordisk Inc. Plainsboro, NJ. FDA Briefing Document, Sept 2014.</p>\n<p>9. Data on File at Novo Nordisk Inc. Plainsboro, NJ. NN8022-1923 (SCALE Maintenance), Oct 2013.</p>\n<p>10. &#xA0;Victoza&#xAE; Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.</p>"
            ]
        }
    ]
}